Share Market Newspaper

Pulmonary Arterial Hypertension Disorder Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Pulmonary Arterial Hypertension Disorder Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

September 23
20:58 2022
Pulmonary Arterial Hypertension Disorder Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Pulmonary Arterial Hypertension Disorder Market
DelveInsight’s Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

The Pulmonary Arterial Hypertension market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted Pulmonary Arterial Hypertension symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Pulmonary Arterial Hypertension symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Some of the key facts of the Pulmonary Arterial Hypertension Disorder Market Report:

  • Hypertension in the United States” conducted by Kirson et.al. (2011), the prevalence of Pulmonary Arterial Hypertension was observed to be 109 per million individuals (PMI) among the population of fewer than 65 years old. The prevalence of Pulmonary Arterial Hypertension was found to be 451 per million individuals (PMI) among age groups older than 65 years.
  •  An increase in the aging population is leading to an increase in prevalent cases of PAH. The disease is more prevalent among women as compared to males. Improvement in diagnostic imaging technologies has increased the number of people being diagnosed with PAH. It is most common among younger people as compared to older people. It is most commonly diagnosed in WHO Functional Class III and IV.
  •  

Key benefits of the Pulmonary Arterial Hypertension Market report:

 

  •  The report covers the descriptive overview of Pulmonary Arterial Hypertension (PAH), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Pulmonary Arterial Hypertension (PAH) epidemiology and treatment in the 7MM
  •  Additionally, an all-inclusive account of both the current and emerging therapies for Pulmonary Arterial Hypertension (PAH) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Pulmonary Arterial Hypertension (PAH) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  •  The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Pulmonary Arterial Hypertension (PAH) market

 

Got queries? Click here to know more about the Pulmonary Arterial Hypertension Market Landscape

Pulmonary Arterial Hypertension  Overview

Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension that is characterized by elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to right ventricular dysfunction and vessel obstruction. Pulmonary hypertension (PH) is a progressive condition that leads to the narrowing of the arteries of the lungs and heart. It is most common among patients with lung and heart conditions.

Pulmonary Arterial Hypertension (PAH) is characterized by similar symptoms that appear during heart and lung conditions. Several techniques and blood tests such as Chest X-Ray, Blood Tests, Cardiac Catheterization, Electrocardiogram, and Echocardiogram are used for diagnosing PAH. Cardiac Catheterization involves the insertion of a thin tube into a vein of the neck. Right heart catheterization is used for measuring the amount of pressure developed in pulmonary arteries. It is also used for assessing the functioning of the heart. Blood tests are mostly recommended to determine the presence of connective tissue disease, Human Immunodeficiency Virus (HIV) infection, and Sickle Cell Anemia.The main purpose of the treatment of Pulmonary Arterial Hypertension is to improve the symptoms of patients and slowing the rate of clinical deterioration. 

General measures, supportive therapy, pharmacological treatment, and Surgical Treatment are used for treating Pulmonary Arterial Hypertension (PAH). Patients are advised to adopt lifestyle changes regarding the general activities of daily living. Women with Pulmonary Arterial Hypertension are recommended to avoid pregnancy. Vaccinations against influenza and pneumococcal infection are also recommended. Patients are advised to avoid undergoing excessive physical activity. Oral anticoagulants, supplemental oxygen therapy, and cardiovascular drugs are used as supportive therapy for treating Pulmonary Arterial Hypertension. 

 

Pulmonary Arterial Hypertension Epidemiology Insights:

 

  • As per Levine (2021), significant progress in the field of PAH pathophysiology and treatment has occurred in the 2 decades since the NIH registry. Contemporary PAH registries vary in their study populations, study design, and cohorts. The 2002 French Network on Pulmonary Arterial Hypertension (French PAH) registry included 674 people with PAH.19 The French PAH registry found an estimated survival rate among those idiopathic/familial/anorexigen-associated PAH of 82.9% at 1 year and 58.2% at 3 years.20 This is a markedly higher survival rate compared with the NIH registry but consistent with other more recent PAH registry findings.
  •  According to Schwab (2021), women are more likely to have PAH, with registries reporting a 65-80% female predominance of the disease. [8] Interestingly, while prior studies suggested a mean age of diagnosis in the thirties, current registries suggest a mean age of diagnosis in the fifties. [8] Although PAH can affect all races, data from the US REVEAL registry suggest a white predominance (73% white vs. 12% African American, 9% Latino, and 3% Asian). 

    

Pulmonary Arterial Hypertension Epidemiological Segmentation 

  • Pulmonary Arterial Hypertension total prevalent patient population
  • Pulmonary Arterial Hypertension sub-type specific prevalence 
  • Pulmonary Arterial Hypertension gender-specific prevalence 

 

Pulmonary Arterial Hypertension Market Outlook 

The Pulmonary Arterial Hypertension (PAH) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Pulmonary Arterial Hypertension (PAH) market trends by analyzing the impact of current Pulmonary Arterial Hypertension (PAH) therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Pulmonary Arterial Hypertension (PAH) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Pulmonary Arterial Hypertension (PAH) market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Pulmonary Arterial Hypertension (PAH) market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @Pulmonary Arterial Hypertension  Market Landscape

 

Pulmonary Arterial Hypertension Key Companies  

  •  Reviva Pharmaceuticals
  •  Cereno Scientific 
  •  Arena Pharmaceuticals
  •  Acceleron Pharma
  • And others.

 

Pulmonary Arterial Hypertension Therapies

  • RP 5063 [Brilaroxazine
  • CS1
  • Ralinepag
  • Sotatercept
  • And others,

 

Table of Contents

  •  Key Insights 
  •  Report Introduction 
  •  Executive Summary of Pulmonary Arterial Hypertension
  •  Disease Background and Overview
  •  Epidemiology and patient population
  •  The United States 
  •  EU 5
  •  Pulmonary Arterial Hypertension  Emerging Therapies
  •  Pulmonary Arterial Hypertension Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  •  Pulmonary Arterial Hypertension Report Methodology
  •  DelveInsight Capabilities
  •  Disclaimer

Click here to read more about Pulmonary Arterial Hypertension market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/